ASCO 2020 – Lung Cancer

Impact of Immune-Related Adverse Events on Checkpoint Inhibitor Consolidation Therapy in Stage III NSCLC

Immune-related adverse events did not affect the clinical benefit of consolidation checkpoint inhibitor therapy after chemoradiation in stage III non–small-cell lung cancer.

Patterns of Acquired Resistance in Patients with NSCLC Who Receive PD-1 Inhibitors

The frequency and durability of outcomes associated with acquired resistance to PD-1 inhibition in non–small-cell lung cancer are presented.

Characteristics of Patients Who Achieve Long-Term Response with PD-1 Blockade

The characteristics of long-term responders to PD-1 blockade are presented.

Smoking Cessation and Lung Cancer: Recent Quitters Benefit Too

For oncologists and others who advocate for smoking cessation, it is important to know whether recent quitters who are diagnosed with lung cancer can achieve a survival benefit.

Weekly Epirubicin as Second-Line Therapy for Malignant Pleural Mesothelioma

Weekly epirubicin was evaluated as a potential “gentle” option for second-line chemotherapy in patients with malignant pleural mesothelioma after failure of first-line pemetrexed-based chemotherapy.

ADAURA Results: Osimertinib as Adjuvant Therapy for EGFR-Mutated NSCLC

Approximately 30% of patients with non–small-cell lung cancer present with early-stage (I-IIIA) disease and undergo surgery. Researchers assessed the use of adjuvant osimertinib in this population.

Retrospective Data Suggest Role for Immunotherapy in Patients with Large-Cell Neuroendocrine Carcinoma

Despite the approval of immune checkpoint inhibitors for patients with lung cancers, their role in rare pulmonary tumors, such as large-cell neuroendocrine carcinoma of the lung, has remained unclear.

Cediranib Combined with Olaparib Is Active in Patients with Platinum-Pretreated SCLC

Patients with platinum-pretreated small-cell lung cancer may benefit from combination use of cediranib, an oral VEGF inhibitor, and olaparib, a PARP inhibitor.

Nationwide Genomic Screening Network Can Be Effective in Identifying Rare Targetable Genetic Alterations

Developing novel targeted therapies for patients with cancer who have rare mutations, such as PI3K/AKT/mTOR pathway alterations, is particularly challenging for researchers.

Combination of Nivolumab, Ipilimumab, and Chemotherapy in Metastatic NSCLC

Combining nivolumab plus ipilimumab with 2 cycles of chemotherapy may be effective in patients undergoing first-line treatment for metastatic non–small-cell lung cancer.